Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Machover

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1979
Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomasM Bayssas, J Gouveia, P Ribaud, et al.
European Journal of Cancer & Clinical Oncology|August 1, 1982
Study of nitrosourea glycosyl analogs--V. An oriented phase II trial of RFCNUG Mathe, P Schein, J S MacDonald, et al.
Medical Oncology (Northwood, London, England)|November 6, 2010
Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysisM Bouchahda, T Macarulla, G Liedo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphomaD Machover, B Delmas-Marsalet, S C Misra, et al.
La Nouvelle Presse Medicale|December 25, 1982
[Treatment of acute myeloid leukemia with a protocol combining intensive induction chemotherapy, early consolidation treatment, splenectomy and long-term maintenance chemotherapy. Preliminary study]D Machover, L Schwarzenberg, E D'Hubert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidinesD Machover, E Diaz-Rubio, A de Gramont, et al.
La Nouvelle Presse Medicale|July 2, 1977
[Acute lymphatic leukemia in children: results of ICIG-ALL protocols 9 and 10, involving respectively short and long chemotherapy before immunotherapy. Identifying two groups of patients according to prognostics]G Mathé, F de Vassal, L Schwarzenberg, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1977
Results in children of acute lymphoid leukemia: protocol ICIG-ALL 9 consisting of chemotherapy for only 9 months followed by active immunotherapy: comparison with the results of more prolonged chemotherapy protocols. Recognition of two groups of acute lymphoid leukemias from prognostic parametersG Mathé, F De Vassal, L Schwarzenberg, et al.
Archives Francaises De Pediatrie|August 1, 1977
[Results of 3 protocols of treatment of acute lymphoid leukemia in children]G Mathé, F de Vassal, L Schwarzenberg, et al.
Medical and Pediatric Oncology|January 1, 1978
Preliminary results of three protocols for the treatment of acute lymphoid leukaemia of children: distinction of two groups of patients according to predictable prognosisG Mathé, F De Vassal, L Schwarzenberg, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Cancer Chemotherapy and Pharmacology|January 1, 1979
Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomasM Bayssas, J Gouveia, P Ribaud, et al.
European Journal of Cancer & Clinical Oncology|August 1, 1982
Study of nitrosourea glycosyl analogs--V. An oriented phase II trial of RFCNUG Mathe, P Schein, J S MacDonald, et al.
Medical Oncology (Northwood, London, England)|November 6, 2010
Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysisM Bouchahda, T Macarulla, G Liedo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphomaD Machover, B Delmas-Marsalet, S C Misra, et al.
La Nouvelle Presse Medicale|December 25, 1982
[Treatment of acute myeloid leukemia with a protocol combining intensive induction chemotherapy, early consolidation treatment, splenectomy and long-term maintenance chemotherapy. Preliminary study]D Machover, L Schwarzenberg, E D'Hubert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidinesD Machover, E Diaz-Rubio, A de Gramont, et al.
La Nouvelle Presse Medicale|July 2, 1977
[Acute lymphatic leukemia in children: results of ICIG-ALL protocols 9 and 10, involving respectively short and long chemotherapy before immunotherapy. Identifying two groups of patients according to prognostics]G Mathé, F de Vassal, L Schwarzenberg, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1977
Results in children of acute lymphoid leukemia: protocol ICIG-ALL 9 consisting of chemotherapy for only 9 months followed by active immunotherapy: comparison with the results of more prolonged chemotherapy protocols. Recognition of two groups of acute lymphoid leukemias from prognostic parametersG Mathé, F De Vassal, L Schwarzenberg, et al.
Archives Francaises De Pediatrie|August 1, 1977
[Results of 3 protocols of treatment of acute lymphoid leukemia in children]G Mathé, F de Vassal, L Schwarzenberg, et al.
Medical and Pediatric Oncology|January 1, 1978
Preliminary results of three protocols for the treatment of acute lymphoid leukaemia of children: distinction of two groups of patients according to predictable prognosisG Mathé, F De Vassal, L Schwarzenberg, et al.
Pageof 8